NASDAQ:FGEN - FibroGen Stock Price, Price Target & More

$46.55 -1.60 (-3.32 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$46.55

Today's Range$46.50 - $48.15

52-Week Range$25.35 - $63.00

Volume312,139 shs

Average Volume584,076 shs

Market Capitalization$4.04 billion

P/E Ratio-26.91

Dividend YieldN/A

Beta1.89

About FibroGen (NASDAQ:FGEN)

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:FGEN

CUSIPN/A

Webwww.fibrogen.com

Phone415-978-1200

Debt

Debt-to-Equity Ratio0.17%

Current Ratio9.70%

Quick Ratio9.70%

Price-To-Earnings

Trailing P/E Ratio-26.91

Forward P/E Ratio-34.48

P/E GrowthN/A

Sales & Book Value

Annual Sales$125.67 million

Price / Sales30.62

Cash FlowN/A

Price / CashN/A

Book Value$7.09 per share

Price / Book6.57

Profitability

EPS (Most Recent Fiscal Year)($1.73)

Net Income$-126,200,000.00

Net Margins-100.43%

Return on Equity-32.08%

Return on Assets-18.17%

Miscellaneous

Employees423

Outstanding Shares82,670,000

How to Become a New Pot Stock Millionaire

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen (NASDAQ:FGEN) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.01. The biopharmaceutical company had revenue of $42.51 million for the quarter, compared to analysts' expectations of $45.37 million. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

7 brokerages have issued 1 year target prices for FibroGen's shares. Their predictions range from $31.00 to $88.00. On average, they expect FibroGen's share price to reach $66.6667 in the next twelve months. View Analyst Ratings for FibroGen.

What are Wall Street analysts saying about FibroGen stock?

Here are some recent quotes from research analysts about FibroGen stock:

1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (3/5/2018)
2. Mizuho analysts commented, "We believe Fibrogen is fairly priced. KeyPoints Earnings. For 3Q17, Fibrogen’s financials missed street estimates on reported revenue of $27.3 mil vs. consensus of $39.7 mil and missed on reported EPS of $(0.50) vs. consensus of $(0.37). License and milestone revenue recognized in the quarter appeared lower than expectations. R&D and SG&A expenses were approximately in-line with our prior projections. For 4Q17, Fibrogen expects to recognize a $15 mil milestone from AstraZeneca (AZN, not rated) related to roxadustat’s NDA filing in October 2017 in China. Quarterly earnings are usually not a driver for development stage companies like Fibrogen. In our opinion, news flow related to the pipeline development are more likely to be a catalyst. Progress for pamrevlumab in IPF. During the quarter Fibrogen reported positive topline results from their phase II trial for pamrevlumab in moderate- to-severe idiopathic pulmonary fibrosis (IPF) patients." (11/9/2017)

Who are some of FibroGen's key competitors?

Some companies that are related to FibroGen include SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP) and Array Biopharma (ARRY).

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
Mr. Pat Cotroneo, VP of Fin. & CFO (Age 54)
Dr. K. Peony Yu M.D., Chief Medical Officer (Age 56)
Dr. Barry A. Berkowitz, Founder
Dr. Michael J. Martinelli Ph.D., VP of Technical Devel.

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Has FibroGen been receiving favorable news coverage?

News articles about FGEN stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. FibroGen earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.42 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $46.55.

How big of a company is FibroGen?

FibroGen has a market capitalization of $4.04 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		158 (Vote Outperform)
Underperform Votes:		138 (Vote Underperform)
Total Votes:		296

MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

FibroGen (NASDAQ:FGEN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for FibroGen in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 43.22%. The high price target for FGEN is $88.00 and the low price target for FGEN is $31.00. There are currently 2 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.86	2.86	2.86	2.88
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$66.6667	$66.6667	$65.6667	$65.6667
Price Target Upside:	43.22% upside	14.06% upside	21.49% upside	9.26% upside

FibroGen (NASDAQ:FGEN) Consensus Price Target History

Price Target History for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/29/2018	Mizuho	Reiterated Rating	Hold	$61.00	Low
2/28/2018	Leerink Swann	Reiterated Rating	Outperform	$80.00 -> $88.00	High
9/14/2017	Stifel Nicolaus	Reiterated Rating	Buy	$80.00	Low
9/12/2017	Jefferies Group	Reiterated Rating	Buy	$75.00	Low
8/9/2017	William Blair	Reiterated Rating	Outperform		Medium
8/8/2017	Citigroup	Boost Price Target	Top Pick	$48.00 -> $65.00	High
7/21/2017	Goldman Sachs	Downgrade	Buy -> Neutral	$31.00	Medium
1/18/2017	Royal Bank of Canada	Reiterated Rating	Buy		N/A
8/9/2016	Credit Suisse Group	Reiterated Rating	Buy	$37.00	N/A

(Data available from 4/19/2016 forward)

FibroGen (NASDAQ:FGEN) Earnings History and Estimates Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.44)
2019 EPS Consensus Estimate: $1.08

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($0.52)	($0.48)	($0.50)
Q2 2018	3	($0.55)	($0.51)	($0.53)
Q3 2018	3	($0.53)	$0.00	($0.34)
Q4 2018	3	($0.75)	$0.62	($0.06)
Q1 2019	1	$2.63	$2.63	$2.63
Q2 2019	1	($0.79)	($0.79)	($0.79)
Q3 2019	1	($0.77)	($0.77)	($0.77)
Q4 2019	1	$0.01	$0.01	$0.01

FibroGen (NASDAQ FGEN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.55)					N/A
2/27/2018	Q4 2017	($0.28)	($0.27)	$45.37 million	$42.51 million	View	N/A
11/8/2017	Q3 2017	($0.37)	($0.50)	$41.34 million	$27.27 million	View	N/A
8/7/2017	Q2 2017	($0.47)	($0.48)	$34.80 million	$29.00 million	View	Listen
5/9/2017	Q1 2017	($0.63)	($0.52)	$26.02 million	$26.89 million	View	Listen
3/1/2017	Q4 2016	($0.53)	($0.54)	$19.29 million	$31.91 million	View	Listen
11/8/2016	Q3	($0.63)	($0.38)	$24.30 million	$30.10 million	View	Listen
8/8/2016	Q2	$0.36	$0.35	$80.58 million	$89.28 million	View	Listen
5/9/2016	Q116	($0.56)	($0.45)	$16.89 million	$28.28 million	View	Listen
2/29/2016	Q4	($0.54)	($0.85)	$40.44 million	$24.44 million	View	Listen
11/12/2015	Q3	($0.6050)	($0.74)	$28.74 million	$19.54 million	View	Listen
8/13/2015	Q215	$0.73	$0.83	$111.75 million	$120.55 million	View	Listen
5/12/2015	Q115	($0.53)	($0.78)	$34.00 million	$16.30 million	View	N/A
3/26/2015	Q414	($0.90)	($0.82)	$16.49 million	$16.11 million	View	Listen

(Earnings results data provided by Zacks Investment Research)

FibroGen (NASDAQ:FGEN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 61.39%

Insider Trading History for FibroGen (NASDAQ:FGEN)

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	K Peony Yu	Insider	Sell	7,500	$47.81	$358,575.00	156,233
4/9/2018	Jorma Routti	Director	Sell	6,000	$46.59	$279,540.00	133,840
4/5/2018	Thomas B Neff	CEO	Sell	39,636	$45.59	$1,807,005.24	2,950,813
3/21/2018	Thomas B Neff	CEO	Sell	39,636	$50.95	$2,019,454.20	2,969,251
3/15/2018	Pat Cotroneo	VP	Sell	42,026	$52.85	$2,221,074.10	168,334
3/15/2018	Roberto Pedro Rosenkranz	Director	Sell	1,000	$52.34	$52,340.00	24,000
3/14/2018	K Peony Yu	Insider	Sell	9,891	$53.20	$526,201.20	128,333
3/13/2018	Pat Cotroneo	CFO	Sell	5,932	$54.61	$323,946.52	168,334
3/12/2018	Thomas F Kearns Jr	Director	Sell	18,000	$55.00	$990,000.00	135,064
3/9/2018	Rory B Riggs	Director	Sell	22,905	$55.75	$1,276,953.75	411,295
3/8/2018	Pat Cotroneo	VP	Sell	1,894	$53.12	$100,609.28	176,160
3/8/2018	Thomas B Neff	CEO	Sell	39,636	$53.14	$2,106,257.04	2,907,425
2/23/2018	Thomas B Neff	CEO	Sell	39,636	$56.66	$2,245,775.76	2,955,614
2/16/2018	Pat Cotroneo	VP	Sell	49,500	$55.96	$2,770,020.00	207,392
2/15/2018	Kalevi Kurkijarvi	Director	Sell	6,000	$55.69	$334,140.00	26,000
2/8/2018	K Peony Yu	Insider	Sell	7,500	$53.97	$404,775.00	144,986
1/30/2018	Thomas B Neff	CEO	Sell	38,636	$61.40	$2,372,250.40	2,958,105
1/29/2018	K Peony Yu	Insider	Sell	10,000	$62.00	$620,000.00	152,086
1/26/2018	Roberto Pedro Rosenkranz	Director	Sell	6,000	$60.00	$360,000.00	29,000
1/22/2018	Pat Cotroneo	CFO	Sell	25,000	$48.72	$1,218,000.00	208,852
1/22/2018	Roberto Pedro Rosenkranz	Director	Sell	71	$50.00	$3,550.00	36,929
1/18/2018	Kalevi Kurkijarvi	Director	Sell	6,000	$47.38	$284,280.00	28,000
1/18/2018	Thomas B Neff	CEO	Sell	18,900	$47.64	$900,396.00	2,981,447
1/5/2018	Thomas B Neff	CEO	Sell	38,636	$47.61	$1,839,459.96	3,029,887
12/29/2017	Thomas B Neff	CEO	Sell	38,636	$48.39	$1,869,596.04
12/28/2017	Thomas B Neff	CEO	Sell	18,900	$48.29	$912,681.00	3,071,705
12/21/2017	Thomas B Neff	CEO	Sell	38,636	$44.66	$1,725,483.76	3,022,934
12/18/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$42.80	$85,600.00	22,000
12/14/2017	K Peony Yu	Insider	Sell	2,851	$43.70	$124,588.70	162,086
12/14/2017	Thomas B Neff	CEO	Sell	18,900	$42.71	$807,219.00	3,060,887
12/12/2017	Kalevi Kurkijarvi	Director	Sell	12,000	$44.45	$533,400.00	36,000
12/11/2017	Pat Cotroneo	VP	Sell	2,851	$46.00	$131,146.00	183,852
12/4/2017	Gerald Lema	Director	Buy	3,500	$46.70	$163,450.00	3,500
12/1/2017	Jorma Routti	Director	Sell	12,000	$47.25	$567,000.00	133,840
11/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$46.65	$93,300.00	24,000
11/16/2017	Thomas B Neff	CEO	Sell	18,900	$46.60	$880,740.00	3,109,555
11/15/2017	Thomas F Kearns Jr	Director	Sell	18,000	$45.22	$813,960.00	156,564
11/6/2017	K Peony Yu	Insider	Sell	7,500	$55.37	$415,275.00	170,104
10/31/2017	Thomas B Neff	CEO	Sell	38,636	$56.13	$2,168,638.68	3,144,573
10/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$52.24	$104,480.00	26,000
10/17/2017	Thomas B Neff	CEO	Sell	38,636	$55.02	$2,125,752.72	3,176,861
10/16/2017	Thomas B Neff	CEO	Sell	18,900	$54.83	$1,036,287.00	3,176,861
10/4/2017	K Peony Yu	Insider	Sell	15,000	$60.00	$900,000.00
10/3/2017	Thomas B Neff	CEO	Sell	38,636	$55.09	$2,128,457.24
10/2/2017	K Peony Yu	Insider	Sell	40,000	$54.63	$2,185,200.00
10/2/2017	Thomas B Neff	CEO	Sell	18,900	$54.45	$1,029,105.00	3,217,455
9/20/2017	Thomas B Neff	CEO	Sell	38,636	$53.46	$2,065,480.56	3,246,754
9/18/2017	Kalevi Kurkijarvi	Director	Sell	4,000	$46.65	$186,600.00	30,000
9/14/2017	K Peony Yu	Insider	Sell	2,851	$51.00	$145,401.00	185,546
9/14/2017	Thomas B Neff	CEO	Sell	38,636	$51.67	$1,996,322.12	3,297,655
9/13/2017	Rory B Riggs	Director	Sell	25,000	$51.92	$1,298,000.00	435,200
9/13/2017	Thomas B Neff	CEO	Sell	18,900	$51.29	$969,381.00	3,297,655
9/11/2017	Pat Cotroneo	VP	Sell	2,851	$49.45	$140,981.95	157,405
9/1/2017	Jorma Routti	Director	Sell	12,000	$47.36	$568,320.00	133,840
8/29/2017	Thomas B Neff	CEO	Sell	38,636	$43.73	$1,689,552.28	3,330,780
8/28/2017	Thomas B Neff	CEO	Sell	18,900	$43.04	$813,456.00	3,330,780
8/21/2017	K Peony Yu	Insider	Sell	7,500	$41.03	$307,725.00	191,507
8/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$40.74	$81,480.00	30,000
8/8/2017	K Peony Yu	Insider	Sell	37,500	$50.58	$1,896,750.00	236,507
8/8/2017	Pat Cotroneo	VP	Sell	95,000	$50.61	$4,807,950.00	173,366
8/2/2017	Pat Cotroneo	VP	Sell	28,346	$33.97	$962,913.62	170,666
8/1/2017	K Peony Yu	Insider	Sell	10,000	$33.48	$334,800.00	226,507
7/25/2017	Thomas B Neff	CEO	Sell	38,636	$35.09	$1,355,737.24	3,330,780
7/24/2017	Thomas B Neff	CEO	Sell	18,900	$35.06	$662,634.00	3,330,780
7/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$33.45	$66,900.00	32,000
7/10/2017	K Peony Yu	Insider	Sell	5,000	$32.98	$164,900.00	216,507
7/7/2017	Thomas B Neff	CEO	Sell	38,636	$33.38	$1,289,669.68	3,330,780
7/6/2017	Pat Cotroneo	VP	Sell	4,000	$34.00	$136,000.00	167,366
7/6/2017	Thomas B Neff	CEO	Sell	18,900	$33.53	$633,717.00	3,330,780
6/22/2017	Pat Cotroneo	VP	Sell	3,000	$32.00	$96,000.00	166,366
6/22/2017	Thomas B Neff	CEO	Sell	38,636	$31.52	$1,217,806.72	3,330,780
6/19/2017	Pat Cotroneo	VP	Sell	5,500	$30.00	$165,000.00	168,866
6/16/2017	Thomas B Neff	CEO	Sell	38,636	$29.40	$1,135,898.40	3,330,780
6/15/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$28.50	$57,000.00	34,000
6/14/2017	K Peony Yu	Insider	Sell	3,721	$28.95	$107,722.95	221,507
6/12/2017	Pat Cotroneo	VP	Sell	2,891	$28.75	$83,116.25	163,366
6/12/2017	Toshinari Tamura	Director	Sell	30,000	$28.89	$866,700.00	60,000
6/6/2017	Thomas F Kearns Jr	Director	Sell	18,000	$28.71	$516,780.00	156,564
5/31/2017	Thomas B Neff	CEO	Sell	38,636	$26.21	$1,012,649.56	3,345,941
5/16/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$27.40	$54,800.00	36,000
5/16/2017	Thomas B Neff	CEO	Sell	38,636	$27.70	$1,070,217.20	3,345,941
5/15/2017	Thomas B Neff	CEO	Sell	18,900	$27.75	$524,475.00	3,345,941
5/10/2017	K Peony Yu	Insider	Sell	5,000	$26.38	$131,900.00	227,346
4/25/2017	K Peony Yu	Insider	Sell	5,000	$28.00	$140,000.00	236,046
4/25/2017	Pat Cotroneo	VP	Sell	6,500	$28.00	$182,000.00	164,405
4/25/2017	Thomas B Neff	CEO	Sell	38,636	$26.92	$1,040,081.12	3,345,941
4/24/2017	Thomas B Neff	CEO	Sell	18,900	$26.35	$498,015.00	3,345,941
4/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$25.25	$50,500.00	38,000
4/13/2017	Thomas B Neff	CEO	Sell	38,636	$24.79	$957,786.44	3,345,941
4/4/2017	Thomas B Neff	CEO	Sell	38,636	$23.92	$924,173.12	3,345,941
3/21/2017	Thomas B Neff	CEO	Sell	38,636	$24.34	$940,400.24	3,345,941
3/20/2017	Thomas B Neff	CEO	Sell	18,900	$24.88	$470,232.00	3,345,941
3/15/2017	Thomas B Neff	CEO	Sell	38,636	$25.07	$968,604.52	3,353,983
2/16/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$24.45	$48,900.00	40,000
2/14/2017	Thomas B Neff	CEO	Sell	38,636	$23.94	$924,945.84	3,274,061
2/13/2017	Thomas B Neff	CEO	Sell	18,900	$23.97	$453,033.00	3,274,061
2/9/2017	Thomas B Neff	CEO	Sell	37,798	$23.46	$886,741.08	3,278,868
1/27/2017	Thomas B Neff	CEO	Sell	37,798	$23.29	$880,315.42	3,288,484
1/19/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$24.90	$49,800.00	42,000
1/12/2017	Thomas B Neff	CEO	Sell	37,798	$23.85	$901,482.30	3,298,100
1/11/2017	Pat Cotroneo	VP	Sell	6,500	$24.00	$156,000.00	138,748
1/10/2017	K Peony Yu	Insider	Sell	5,000	$23.56	$117,800.00	202,448
12/28/2016	Thomas B Neff	CEO	Sell	37,798	$20.74	$783,930.52	3,307,718
12/16/2016	Rory B Riggs	Director	Sell	20,000	$20.87	$417,400.00	460,200
12/13/2016	Thomas B Neff	CEO	Sell	37,798	$21.24	$802,829.52	3,317,334
12/12/2016	Pat Cotroneo	VP	Sell	2,344	$22.05	$51,685.20	132,248
12/12/2016	Thomas B Neff	CEO	Sell	18,899	$21.48	$405,950.52	3,317,334
11/29/2016	Thomas B Neff	CEO	Sell	37,798	$22.80	$861,794.40	3,331,639
11/28/2016	Thomas B Neff	CEO	Sell	18,899	$22.74	$429,763.26	3,331,639
11/18/2016	Thomas F Kearns Jr	Director	Sell	18,000	$22.40	$403,200.00	165,564
11/17/2016	Thomas B Neff	CEO	Sell	37,798	$22.29	$842,517.42	3,341,255
11/1/2016	Thomas B Neff	CEO	Sell	37,798	$16.76	$633,494.48	3,350,871
10/19/2016	Thomas B Neff	CEO	Sell	37,798	$17.75	$670,914.50	3,360,487
10/18/2016	Thomas B Neff	CEO	Sell	18,899	$17.94	$339,048.06	3,360,487
10/4/2016	Thomas B Neff	CEO	Sell	18,899	$20.67	$390,642.33	3,370,103
10/3/2016	Thomas B Neff	CEO	Sell	18,899	$20.55	$388,374.45	3,370,103
9/21/2016	Thomas B Neff	CEO	Sell	37,798	$21.66	$818,704.68	3,379,719
9/14/2016	K Peony Yu	Insider	Sell	2,345	$18.66	$43,757.70	206,502
9/12/2016	Pat Cotroneo	VP	Sell	2,345	$18.22	$42,725.90	134,359
9/9/2016	Thomas B Neff	CEO	Sell	37,798	$18.99	$717,784.02	3,389,335
8/26/2016	Thomas B Neff	CEO	Sell	37,798	$17.80	$672,804.40	3,403,639
7/27/2016	Thomas B Neff	CEO	Sell	37,798	$18.38	$694,727.24	3,413,255
7/13/2016	Thomas B Neff	CEO	Sell	27,000	$17.50	$472,500.00	3,412,664
6/29/2016	Thomas B Neff	CEO	Sell	27,000	$16.02	$432,540.00	3,439,764
6/15/2016	Pat Cotroneo	CFO	Sell	1,796	$16.49	$29,616.04	138,114
6/15/2016	Thomas B Neff	CEO	Sell	27,000	$16.48	$444,960.00	3,466,664
6/10/2016	K Peony Yu	Insider	Sell	2,344	$17.96	$42,098.24	210,257
6/3/2016	Thomas B Neff	CEO	Sell	27,000	$18.99	$512,730.00	3,507,164
5/20/2016	Thomas B Neff	CEO	Sell	27,000	$17.68	$477,360.00	3,526,053
5/16/2016	Pat Cotroneo	CFO	Sell	6,107	$17.60	$107,483.20	141,868
5/3/2016	Thomas B Neff	CEO	Sell	27,000	$17.78	$480,060.00	3,552,353
4/20/2016	Thomas B Neff	CEO	Sell	27,000	$19.98	$539,460.00	3,579,353
4/19/2016	Thomas B Neff	CEO	Sell	13,500	$20.21	$272,835.00	3,579,353
4/5/2016	Thomas B Neff	CEO	Sell	27,000	$21.11	$569,970.00	3,606,353
4/1/2016	Frank H Md Valone	Insider	Sell	10,750	$21.11	$226,932.50	115,434
3/22/2016	Thomas B Neff	CEO	Sell	27,000	$18.74	$505,980.00	3,633,453
3/8/2016	Thomas B Neff	CEO	Sell	27,000	$19.62	$529,740.00	3,667,175
3/1/2016	Frank H Md Valone	Insider	Sell	10,750	$16.84	$181,030.00	115,133
2/23/2016	Thomas B Neff	CEO	Sell	27,000	$19.11	$515,970.00	3,596,207
2/22/2016	Thomas B Neff	CEO	Sell	13,500	$19.81	$267,435.00	3,596,207
2/16/2016	Frank H. Md Valone	insider	Sell	10,750	$18.41	$197,907.50	96,840
2/10/2016	Thomas B. Neff	CEO	Sell	27,000	$15.31	$413,370.00	3,609,407
1/29/2016	Thomas B. Neff	CEO	Sell	27,000	$19.41	$524,070.00	3,636,407
1/21/2016	Thomas F Kearns Jr	Director	Sell	1,572	$22.08	$34,709.76	160,564
1/14/2016	Thomas B. Neff	CEO	Sell	27,000	$23.69	$639,630.00	3,663,407
12/24/2015	Thomas F. Kearns, Jr.	Director	Sell	7,800	$30.88	$240,864.00	162,136
12/23/2015	Thomas B. Neff	CEO	Sell	27,000	$30.10	$812,700.00	3,690,407
12/11/2015	Thomas B. Neff	CEO	Sell	27,000	$29.59	$798,930.00	3,717,407
12/10/2015	K Peony Yu	VP	Sell	1,093	$28.96	$31,653.28	176,595
12/8/2015	Miguel Madero	Director	Sell	40,386	$30.49	$1,231,369.14	55,614
11/30/2015	K Peony Yu	VP	Sell	5,000	$30.00	$150,000.00	178,345
11/25/2015	Pat Cotroneo	CFO	Sell	5,000	$30.00	$150,000.00	107,775
11/24/2015	Thomas B. Neff	CEO	Sell	13,500	$28.98	$391,230.00	3,746,689
11/24/2015	Thomas F. Kearns, Jr.	Director	Sell	3,900	$29.00	$113,100.00	169,936
11/23/2015	Thomas B. Neff	CEO	Sell	13,500	$27.99	$377,865.00	3,746,689
11/23/2015	Thomas F. Kearns, Jr.	Director	Sell	3,900	$28.02	$109,278.00	169,936
11/17/2015	K Peony Yu	VP	Sell	5,000	$28.00	$140,000.00	183,345
11/10/2015	K Peony Yu	VP	Sell	5,000	$25.62	$128,100.00	187,904
11/9/2015	K Peony Yu	VP	Sell	2,500	$25.00	$62,500.00	187,904
11/2/2015	Frank H. Md Valone	insider	Sell	10,000	$23.18	$231,800.00	84,044
10/30/2015	Thomas B. Neff	CEO	Sell	27,000	$24.06	$649,620.00	3,773,689
10/21/2015	Thomas F. Kearns, Jr.	Director	Sell	7,800	$23.83	$185,874.00	177,736
10/19/2015	Frank H. Md Valone	insider	Sell	10,000	$23.00	$230,000.00	84,044
10/19/2015	K Peony Yu	VP	Sell	5,000	$24.00	$120,000.00	192,904
10/16/2015	K Peony Yu	VP	Sell	5,000	$21.46	$107,300.00	197,904
10/16/2015	Thomas B. Neff	CEO	Sell	27,000	$21.86	$590,220.00	3,800,689
10/2/2015	Thomas B. Neff	CEO	Sell	27,000	$21.59	$582,930.00	3,827,689
10/1/2015	Frank H. Md Valone	insider	Sell	10,000	$21.38	$213,800.00	84,044
9/18/2015	Thomas B. Neff	CEO	Sell	27,000	$29.10	$785,700.00	3,854,689
9/15/2015	Pat Cotroneo	CFO	Sell	1,093	$27.95	$30,549.35	107,498
9/14/2015	Rory B. Riggs	Director	Sell	50,000	$27.61	$1,380,500.00	480,200
9/11/2015	Miguel Madero	Director	Sell	20,600	$27.66	$569,796.00	12,000
9/10/2015	K Peony Yu	VP	Sell	1,093	$27.84	$30,429.12	202,904
9/10/2015	Pat Cotroneo	CFO	Sell	7,500	$27.33	$204,975.00	107,251
9/4/2015	Thomas B. Neff	CEO	Sell	13,500	$22.88	$308,880.00	3,862,751
9/3/2015	Thomas B. Neff	CEO	Sell	13,500	$22.92	$309,420.00	3,866,782
9/1/2015	Frank H. Md Valone	insider	Sell	10,000	$23.58	$235,800.00	84,044
7/23/2015	Thomas B Neff	CEO	Sell	27,000	$24.71	$667,170.00
7/20/2015	Frank H Md Valone	Insider	Sell	1,000	$23.70	$23,700.00
7/20/2015	Pat Cotroneo	CFO	Sell	7,881	$23.47	$184,967.07
7/9/2015	Thomas B Neff	CEO	Sell	27,000	$22.11	$596,970.00
7/6/2015	K Peony Yu	VP	Sell	5,381	$22.69	$122,094.89
6/25/2015	Thomas B Neff	CEO	Sell	27,000	$23.57	$636,390.00

(Data available from 1/1/2013 forward)

FibroGen (NASDAQ FGEN) News Headlines

Source:

Date	Headline
	Form 4 FIBROGEN INC For: Apr 16 Filed by: Yu K Peony www.streetinsider.com - April 19 at 9:10 AM
	Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock www.americanbankingnews.com - April 18 at 7:28 PM
	FibroGen (FGEN) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 14 at 10:53 PM
	FibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 Million www.americanbankingnews.com - April 14 at 2:02 AM
	Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - April 12 at 9:16 PM
	FibroGen (FGEN) Rating Reiterated by Jefferies Group www.americanbankingnews.com - April 12 at 9:00 PM
	Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00 www.americanbankingnews.com - April 12 at 9:00 PM
	FibroGen (FGEN) Director Sells $279,540.00 in Stock www.americanbankingnews.com - April 11 at 10:37 PM
	William Blair Reiterates Outperform Rating for FibroGen (FGEN) www.americanbankingnews.com - April 11 at 6:13 PM
	A Look at FibroGen’s Cash Flow Generating Capacity finance.yahoo.com - April 9 at 9:25 AM
	Thomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) Stock www.americanbankingnews.com - April 6 at 10:27 PM
	Understanding FibroGen’s Research Pipeline finance.yahoo.com - April 6 at 9:35 AM
	FibroGen's (FGEN) "Hold" Rating Reaffirmed at Mizuho www.americanbankingnews.com - March 31 at 8:16 PM
	FibroGen (FGEN) Given Hold Rating at Mizuho www.americanbankingnews.com - March 29 at 5:16 PM
	FibroGen (FGEN) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - March 28 at 1:38 AM
	$28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter www.americanbankingnews.com - March 28 at 1:02 AM
	Brokerages Expect FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - March 26 at 11:08 PM
	Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences www.prnewswire.com - March 26 at 7:42 AM
	FibroGen (FGEN) Upgraded by ValuEngine to "Hold" www.americanbankingnews.com - March 25 at 6:25 PM
	FibroGen (FGEN) Lifted to C- at TheStreet www.americanbankingnews.com - March 24 at 3:53 PM
	FibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 Shares www.americanbankingnews.com - March 22 at 10:22 PM
	FibroGen (FGEN) Receives Patent for Enhanced Erythropoiesis and Iron Metabolism - StreetInsider.com www.streetinsider.com - March 22 at 4:44 PM
	FibroGen Inc (FGEN) Director Roberto Pedro Rosenkranz Sells 1,000 Shares www.americanbankingnews.com - March 16 at 8:32 PM
	FibroGen Inc (FGEN) Insider Sells $526,201.20 in Stock www.americanbankingnews.com - March 16 at 7:52 PM
	Insider Selling: FibroGen Inc (FGEN) CFO Sells 5,932 Shares of Stock www.americanbankingnews.com - March 16 at 4:08 AM
	FibroGen Inc (FGEN) VP Sells $2,221,074.10 in Stock www.americanbankingnews.com - March 15 at 10:10 PM
	FibroGen Inc (FGEN) Director Thomas F. Kearns, Jr. Sells 18,000 Shares www.americanbankingnews.com - March 13 at 10:11 PM
	Brokerages Anticipate FibroGen Inc (FGEN) Will Post Quarterly Sales of $28.23 Million www.americanbankingnews.com - March 11 at 5:58 AM
	FibroGen Inc (FGEN) Director Sells $1,276,953.75 in Stock www.americanbankingnews.com - March 9 at 9:15 PM
	Brokerages Expect FibroGen Inc (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - March 9 at 4:33 PM
	FibroGen Inc (FGEN) VP Sells $100,609.28 in Stock www.americanbankingnews.com - March 8 at 9:50 PM
	Insider Selling: FibroGen Inc (FGEN) CEO Sells 39,636 Shares of Stock www.americanbankingnews.com - March 8 at 9:15 PM
	Landscape Capital Management L.L.C. Purchases Shares of 26,642 FibroGen Inc (FGEN) www.americanbankingnews.com - March 6 at 1:05 PM
	FibroGen (FGEN) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 5 at 11:14 PM
	FibroGen Inc Expected to Post Q1 2018 Earnings of ($0.50) Per Share (FGEN) www.americanbankingnews.com - March 5 at 2:24 AM
	ValuEngine Lowers FibroGen (FGEN) to Sell www.americanbankingnews.com - March 4 at 6:42 PM
	Teacher Retirement System of Texas Boosts Position in FibroGen Inc (FGEN) www.americanbankingnews.com - March 4 at 7:06 AM
	FibroGen Inc (FGEN) Holdings Increased by State of Wisconsin Investment Board www.americanbankingnews.com - March 3 at 8:44 AM
	FibroGen Inc (FGEN) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - March 3 at 1:26 AM
	Jefferies Group Analysts Decrease Earnings Estimates for FibroGen Inc (FGEN) www.americanbankingnews.com - March 2 at 2:30 PM
	Equities Analysts Issue Forecasts for FibroGen Inc's Q3 2018 Earnings (FGEN) www.americanbankingnews.com - March 2 at 11:33 AM
	FibroGen Inc (FGEN) to Post Q1 2018 Earnings of ($0.52) Per Share, William Blair Forecasts www.americanbankingnews.com - March 2 at 9:30 AM
	BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment www.reuters.com - March 1 at 5:01 PM
	UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer finance.yahoo.com - March 1 at 5:01 PM
	William Blair Comments on FibroGen Inc's Q1 2019 Earnings (FGEN) www.americanbankingnews.com - March 1 at 2:08 PM
	BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients www.reuters.com - March 1 at 8:58 AM
	Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer finance.yahoo.com - March 1 at 8:58 AM
	FibroGen (FGEN) Given "Outperform" Rating at Leerink Swann www.americanbankingnews.com - March 1 at 12:30 AM
	Swiss National Bank Increases Stake in FibroGen Inc (FGEN) www.americanbankingnews.com - February 28 at 5:14 PM
	FibroGen Q4 Earnings Outlook finance.yahoo.com - February 27 at 5:14 PM

FibroGen (NASDAQ:FGEN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement

FibroGen (NASDAQ FGEN) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff